Pfizer has reported positive Phase 2 trial data showing its next-generation 25-valent pneumococcal vaccine candidate (25vPnC, PF-07872412) elicits significantly stronger immune responses than Prevnar 20, especially against the key serotype 3 strain, and is expected to cover up to 90% of disease-causing serotypes in young children. The trial compared 25vPnC against Prevnar 20 in a four‑dose infant schedule and found serotype‑3 antibody levels about 9–15‑fold higher with Pfizer’s 25v candidate after doses 3 and 4, positioning it as a potential successor to Prevnar 20 in pediatric pneumonia prevention. Sources: Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program ... Positive Top-line Results of Pfizer's Phase 3 Study Exploring ... Advisory Committee on Immunization Practices ... - Pfizer Pfizer's Prevnar 13 follow-up hits the mark in phase 3, aims for 2020 ... What You Need to Know About the Prevnar 20 Pneumococcal Vaccine Study 1 Results | PREVNAR 20® (Pn...
- Get link
- X
- Other Apps